Viridian Therapeutics
VRDN
9 hedge funds and large institutions have $406K invested in Viridian Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
18% less funds holding
Funds holding: 11 → 9 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
30% less capital invested
Capital invested by funds: $581K → $406K (-$175K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$39.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.5K |
| 3 |
Goldman Sachs
New York
|
+$6.9K |
| 4 |
ICAS
Investors Capital Advisory Services
Lynnfield,
Massachusetts
|
+$511 |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.8K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$12K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$9.71K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$8K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$5.37K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HighTower Advisors
Chicago,
Illinois
| $210K | +$39.7K | +311 | +20% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $69K | -$20.8K | -163 | -21% |
|
|
PCM
3
Perkins Capital Management
Wayzata,
Minnesota
| $44K | -$9.71K | -76 | -17% |
|
|
4
Citadel Advisors
Miami,
Florida
| $29K | +$16.5K | +129 | +103% |
|
|
ICAS
5
Investors Capital Advisory Services
Lynnfield,
Massachusetts
| $20K | +$511 | +4 | +2% |
|
|
VKH
6
Virtu KCG Holdings
New York
| $12K | -$5.37K | -42 | -29% |
|
7
UBS Group
Zurich,
Switzerland
| $9K | -$1.41K | -11 | -12% |
|
8
Creative Planning
Overland Park,
Kansas
| $7K | – | – | – |
|
|
9
Goldman Sachs
New York
| $6K | +$6.9K | +54 | New |
|
|
10
Nomura Holdings
Tokyo,
Japan
| – | -$12K | -72 | Closed |
|
|
TDC
11
Thompson Davis & Co
Richmond,
Virginia
| – | -$8K | -47 | Closed |
|
VRDN Hedge Fund Activity: Q1 2016 in Review
9 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2016, worth a combined $406K — down 30% from $581K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VRDN and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was HighTower Advisors, adding an estimated $39.7K. The largest seller was Vanguard Group, cutting an estimated $20.8K.
- 9 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2016, down from 11 in Q4 2015.
- Funds reported $406K of Viridian Therapeutics stock for Q1 2016, down 30% quarter-over-quarter.
- 1 fund opened new Viridian Therapeutics positions in Q1 2016 and 3 closed out, a net change of -2 holders.
- The largest Viridian Therapeutics buyer in Q1 2016 was HighTower Advisors, an estimated $39.7K added.
- The largest Viridian Therapeutics seller in Q1 2016 was Vanguard Group, an estimated $20.8K sold.
Based on aggregated 13F filings for Q1 2016.